Table 2 Incidence of adverse events with onset from start of run-in medication to 4 weeks after randomization (all patients)
Preferred term | No. | % | 95% confidence intervals |
|---|---|---|---|
Total number of patients | 41 | 100%; | |
Patients with at least one AE | 37 | 90% | (77–97%) |
Headache | 11 | 27% | (14–43%) |
Nasopharyngitis | 11 | 27% | (14–43%) |
Cough | 8 | 20% | (9–35%) |
Nausea | 8 | 20% | (9–35%) |
Febrile infection | 6 | 15% | (6–29%) |
Diarrhoea | 5 | 12% | (4–26%) |
Dizziness | 4 | 10% | (3–23%) |
Fall | 3 | 7% | (2–20%) |
Fatigue | 3 | 7% | (2–20%) |
Pyrexia | 3 | 7% | (2–20%) |
Abdominal pain | 2 | 5% | (0.6–17%) |
Back pain | 2 | 5% | (0.6–17%) |
Chest pain | 2 | 5% | (0.6–17%) |
Decreased appetite | 2 | 5% | (0.6–17%) |
Muscular weakness | 2 | 5% | (0.6–17%) |
Rash | 2 | 5% | (0.6–17%) |